KALV
KalVista Pharmaceuticals Inc

3,103
Mkt Cap
$822.89M
Volume
590,094.00
52W High
$19.00
52W Low
$9.24
PE Ratio
-4.07
KALV Fundamentals
Price
$16.28
Prev Close
$15.76
Open
$15.67
50D MA
$15.51
Beta
0.94
Avg. Volume
1.3M
EPS (Annual)
-$3.69
P/B
48.40
Rev/Employee
$0.00
$575.29
Loading...
Loading...
News
all
press releases
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences: TD Cowen 46th Annual...
Business Wire·5d ago
News Placeholder
More News
News Placeholder
Benjamin Palleiko Sells 10,034 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin Palleiko sold 10,034 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average...
MarketBeat·5d ago
News Placeholder
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CFO Sells 1,767 Shares of Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CFO Brian Piekos sold 1,767 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average...
MarketBeat·5d ago
News Placeholder
KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $61,890.75 in Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Nicole Sweeny sold 3,975 shares of the business's stock in a transaction dated Monday, February 23rd. The shares were sold at an...
MarketBeat·5d ago
News Placeholder
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 5,354 Shares of Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul Audhya sold 5,354 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, February 23rd. The...
MarketBeat·5d ago
News Placeholder
KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 10,034 Shares
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin Palleiko sold 10,034 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average...
MarketBeat·5d ago
News Placeholder
Wall Street Analysts Think KalVista Pharmaceuticals (KALV) Could Surge 117.1%: Read This Before Placing a Bet
The consensus price target hints at an 117.1% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·6d ago
News Placeholder
Skandinaviska Enskilda Banken AB publ Buys 160,128 Shares of KalVista Pharmaceuticals, Inc. $KALV
Skandinaviska Enskilda Banken AB publ boosted its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 391.9% in the 3rd quarter, according to its most recent disclosure...
MarketBeat·9d ago
News Placeholder
KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $15,570.00 in Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin Palleiko sold 1,038 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Wednesday, February 18th...
MarketBeat·10d ago
News Placeholder
Paul Audhya Sells 1,163 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul Audhya sold 1,163 shares of the company's stock in a transaction that occurred on Wednesday, February 18th. The shares were...
MarketBeat·10d ago
<
1
2
...
>

Latest KALV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.